HC Wainwright Forecasts Weaker Earnings for SOPHiA GENETICS

SOPHiA GENETICS SA (NASDAQ:SOPH) – Equities research analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of SOPHiA GENETICS in a research note issued on Wednesday, November 4th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.94) for the year, down from their prior forecast of ($0.77). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for SOPHiA GENETICS’s current full-year earnings is ($0.77) per share. HC Wainwright also issued estimates for SOPHiA GENETICS’s Q4 2026 earnings at ($0.13) EPS, Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.11) EPS and FY2027 earnings at ($0.49) EPS.

Several other research analysts also recently weighed in on SOPH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, October 15th. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, BTIG Research lifted their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Stock Down 5.0%

Shares of SOPH opened at $6.62 on Friday. The company has a current ratio of 2.29, a quick ratio of 2.55 and a debt-to-equity ratio of 0.70. SOPHiA GENETICS has a 12 month low of $3.83 and a 12 month high of $8.98. The stock’s 50 day moving average is $7.74 and its two-hundred day moving average is $5.98. The firm has a market cap of $555.38 million, a P/E ratio of -6.07 and a beta of 1.09.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The business had revenue of $24.27 million during the quarter, compared to analyst estimates of $24.03 million. SOPHiA GENETICS had a negative return on equity of 128.69% and a negative net margin of 89.18%.

Institutional Trading of SOPHiA GENETICS

A number of institutional investors have recently made changes to their positions in SOPH. Royal Bank of Canada increased its position in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares in the last quarter. AXQ Capital LP acquired a new position in SOPHiA GENETICS in the 2nd quarter valued at $119,000. Hennion & Walsh Asset Management Inc. acquired a new position in SOPHiA GENETICS in the 2nd quarter valued at $567,000. Maven Securities LTD purchased a new position in SOPHiA GENETICS in the 2nd quarter valued at $866,000. Finally, Sowell Financial Services LLC purchased a new position in SOPHiA GENETICS in the 3rd quarter valued at $2,865,000. 31.59% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at SOPHiA GENETICS

In other SOPHiA GENETICS news, Chairman Jurgi Camblong sold 40,172 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $8.13, for a total transaction of $326,598.36. Following the completion of the sale, the chairman directly owned 3,395,650 shares in the company, valued at approximately $27,606,634.50. The trade was a 1.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathy L. Hibbs sold 6,250 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $8.13, for a total value of $50,812.50. Following the transaction, the director directly owned 96,992 shares of the company’s stock, valued at $788,544.96. The trade was a 6.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 170,662 shares of company stock worth $1,372,619 in the last three months. 4.88% of the stock is owned by corporate insiders.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a healthcare technology company that develops data-driven solutions for genomic medicine. Its cloud-based platform uses artificial intelligence, machine learning and advanced analytics to help healthcare organizations analyze and interpret complex biological and clinical data.

The company’s primary offering, the SOPHiA DDM platform, supports next-generation sequencing workflows, including data management, quality control, genomic analysis, variant interpretation and reporting.